Pfizer plans to sell £2bn shares in Haleon, reducing its stake from 32% to 24%.
Pfizer plans to sell around £2bn worth of shares in Haleon, reducing its stake in the consumer-healthcare business from 32% to 24%. The sale comes after Pfizer announced in May 2021 its plans to start a "slow and methodical" sell-down to focus on reducing debt and increasing shareholder returns. Haleon, which produces brands such as Sensodyne toothpaste and Advil painkillers, was spun out of GlaxoSmithKline in July 2022.
March 18, 2024
21 Articles